The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

The Journal of Immunology, 2008, 181, 3449 -3455
Copyright © 2008 by The American Association of Immunologists, Inc.
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pegram, H. J.
Right arrow Articles by Darcy, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pegram, H. J.
Right arrow Articles by Darcy, P. K.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Lymphoma

Adoptive Transfer of Gene-Modified Primary NK Cells Can Specifically Inhibit Tumor Progression In Vivo1

Hollie J. Pegram*, Jacob T. Jackson*, Mark J. Smyth*,{dagger}, Michael H. Kershaw2,*,{dagger} and Phillip K. Darcy2,3,*,{dagger}

* Cancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; and {dagger} Department of Pathology, University of Melbourne, Melbourne, Australia


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
NK cells hold great potential for improving the immunotherapy of cancer. Nevertheless, tumor cells can effectively escape NK cell-mediated apoptosis through interaction of MHC molecules with NK cell inhibitory receptors. Thus, to harness NK cell effector function against tumors, we used Amaxa gene transfer technology to gene-modify primary mouse NK cells with a chimeric single-chain variable fragment (scFv) receptor specific for the human erbB2 tumor-associated Ag. The chimeric receptor was composed of the extracellular scFv anti-erbB2 Ab linked to the transmembrane and cytoplasmic CD28 and TCR-{zeta} signaling domains (scFv-CD28-{zeta}). In this study we demonstrated that mouse NK cells gene-modified with this chimera could specifically mediate enhanced killing of an erbB2+ MHC class I+ lymphoma in a perforin-dependent manner. Expression of the chimera did not interfere with NK cell-mediated cytotoxicity mediated by endogenous NK receptors. Furthermore, adoptive transfer of gene-modified NK cells significantly enhanced the survival of RAG mice bearing established i.p. RMA-erbB2+ lymphoma. In summary, these data suggest that use of genetically modified NK cells could broaden the scope of cancer immunotherapy for patients.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Natural killer cells comprise 5–10% of PBLs and play an important role in the body’s first line of defense against pathogen invasion and malignant transformation (1, 2). Unlike the exquisite Ag specificity observed for T and B lymphocytes, NK cells instead express a number of different activation and inhibition receptors which provide a balance of signals that dictate their overall response (3). This recognition system used by NK cells and the fact that they do not require prior sensitization provides a degree of flexibility to rapidly recognize different pathogens.

Several elegant studies have demonstrated that NK cells can effectively control tumor growth in mice mediated through release of perforin and cytokines (4, 5, 6). Their importance in anti-tumor immunity is further illustrated by the increased incidence of leukemia in patients with dysfunctional NK cells (7). The observation that NK cells can effectively respond to tumor cells exhibiting defective or altered MHC class I has made them promising effectors for immunotherapeutic strategies that target tumor escape variants (8). Nevertheless, tumor cells have developed several mechanisms to impede NK cell function, which include the expression of ligands that interact with NK cell inhibitory receptors (9).

Immunotherapeutic strategies to enhance NK cell anti-tumor activity have included the use of specific cytokines (10) or adoptive transfer of autologous ex vivo IL-2-activated lymphokine killer cells (LAK4; Ref. 11). However, these approaches have only resulted in moderate success in restricted numbers of patients (12). More promising results have been recently achieved in the transplant setting with the use of allogeneic NK cells against acute myeloid leukemia (13, 14). Another emerging approach to address the problem of NK cell-mediated inhibition by tumors involves the genetic modification of NK cells with chimeric single-chain variable fragment (scFv) receptors that directly target tumor-associated Ags (TAA). This approach has successfully been used to enhance tumor recognition by primary T cells (15, 16, 17, 18, 19, 20, 21, 22, 23, 24), and several studies have demonstrated specific killing of tumor target cells following redirection of NK cell lines (25, 26, 27) or primary human NK cells (28) with chimeric receptors. Nevertheless, investigation of whether these genetically engineered primary NK cells can specifically reject tumor in vivo has never been reported and has been hampered by lack of an efficient method for expressing transgenes in mouse NK cells.

In this study we have used Amaxa Nucleofector technology, an electroporation-based procedure, to genetically engineer primary mouse NK cells with an scFv anti-erbB2-CD28-{zeta} chimeric receptor. We and others have shown that this novel receptor design incorporating both costimulatory CD28 and TCR-{zeta} domains linked in the one intracellular domain could optimally trigger activation of transduced PBMC after Ag stimulation (15, 21, 29, 30). The Amaxa system uses optimized electrical parameters to enhance delivery of DNA to the cell nucleus, which increases transfection efficiency and gene expression levels. NK cells expressing the chimeric receptor were demonstrated to enhance target cell killing following receptor ligation. Furthermore, adoptive transfer of scFv-receptor gene-modified NK cells led to significant growth inhibition of erbB2+ T cell lymphomas in mice. These data suggest that gene-modified NK cells may have significant potential as an effective immunotherapy for cancer.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Cell lines

The C57BL/6 murine lymphoma cell lines RMA and RMA-S are T cell lymphomas derived from the Rauscher murine leukemia virus-induced RBL-5 cell line (8). The murine melanoma cell line B16-F10 was obtained from American Type Culture Collection. The erbB2-expressing cell lines RMA-erbB2 and B16-F10-erbB2 were generated by transduction with a retroviral vector (murine stem cell vector) encoding the cDNA for human erbB2. All cell lines were maintained in complete DMEM medium containing 10% (v/v) FCS, 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen). The murine lymphoma cell line YAC-1 was maintained in RPMI 1640 medium (Invitrogen), with 10% FCS (v/v), 2 mM L-glutamine, 0.1 mM non-essential amino acids (Life Technologies), 1 mM sodium pyruvate (Life Technologies), 100 U/ml penicillin, 100 µg/ml streptomycin (Life Technologies), and 5 x 10–5 mM 2ME.

Mice

C57BL/6, C57BL/6-ptprca, and C57BL/6 RAG-1-deficient (RAG-1–/–) mice were purchased from the Walter and Eliza Hall Institute of Medical Research. C57BL/6 perforin (pfp)-deficient (C57BL/6-pfp–/–) and C57BL/6 gld (Fas ligand (FasL) mutant) were bred at the Peter MacCallum Cancer Centre. All mice were housed in specific pathogen free conditions at the Peter MacCallum Cancer Centre and mice 6–12 wk of age were used in all experiments.

Isolation of NK cells

Dissected spleens from C57BL/6 mice were crushed into hypotonic lysis buffer and filtered to create a single cell suspension. NK cells were then selected using anti-DX5 Microbeads or an NK cell isolation beading kit (Miltenyi Biotec) according to manufacturer’s specifications. The cells were then grown in RPMI 1640 medium containing 10% (v/v) FCS, 2 mM L-glutamine, 5 x 10–5 mM 2ME, 100 U/ml penicillin, 100 µg/ml streptomycin (Life Technologies), 2 mM HEPES, and 1000 IU/ml recombinant human IL-2 (Biological Resources Branch Preclinical Repository, National Cancer Institute).

Gene modification of NK cells

Seven-day IL-2-activated mouse NK cells were gene modified by electroporation using the Amaxa Nucleofector system (Amaxa Biosystems). In brief, NK cells were placed in 0.1 ml electroporation solution with either 4 µg pMAX plasmid DNA encoding the scFv {alpha}-erbB2-CD28-{zeta} chimeric receptor or GFP. Following electroporation, the cells were placed into 2 ml Amaxa recovery medium with 600 IU/ml recombinant human IL-2 for 24 h before being used in experiments.

Flow cytometry

Expression of the chimeric scFv receptor on the surface of NK cells was determined by indirect immunofluorescence with a primary c-myc tag Ab (Cell Signaling Technology), followed by staining with a secondary PE-labeled anti-mouse Ig mAb (BD Biosciences). Background fluorescence was determined by staining cells with an isotype control Ab followed by a secondary PE-conjugated anti-mouse Ig mAb. Direct detection of GFP by flow cytometry was examined in transfected vs non-transfected NK cells. Phenotyping of cell surface marker expression on NK cells was determined by staining cells with allophycocyanin-conjugated Abs specific for NK1.1, DX5, CD11b, and CD27 (eBioscience) and biotin-conjugated KLRG1, NKG2D (eBioscience), and biotin- conjugated CD94, CD25, and CD69 (BD Pharmingen). This was the followed by staining with a PerCPCy5.5-streptavidin (BD Pharmingen) Ab. MHC class I expression on tumor cells was determined by staining cells with a PE-conjugated Ab specific for mouse H2kb (BD Biosciences).

Cytotoxicity

The ability of gene-modified mouse NK cells from wild-type (WT) and/or gene-targeted mice to specifically kill tumor targets was assessed in a 4 h 51Cr-release assay. In brief, NK cells were incubated with 1 x 105 51Cr-labeled tumor targets at various E:T ratios in triplicate wells of a 96-well round-bottom plate (in 200 µl of complete DMEM). The percentage of specific release of 51Cr into the supernatant was assessed as described previously (31).

Adoptive transfer

The ability of gene-modified NK cells expressing the {alpha}-erbB2-CD28-{zeta} receptor to enhance the survival of tumor bearing mice was investigated in the following model. C57BL/6 RAG-1–/– mice were injected i.p. with 2 x 105 RMA-parental or RMA-erbB2 tumor cells. Mice were then treated on days 0, 1, days 0, 1, 2, 3 (early model), or days 3, 4 (delayed model) with 2 x 106 (per injection) of {alpha}-erbB2 NK cells or GFP-NK control cells delivered i.p. In some experiments gene-modified NK cells were coadministered with high dose IL-2 (200,000 IU/ml) injected i.p. on days 0, 1, and 2. To investigate the persistence of NK cells in vivo, 2 x 106 donor gene-modified NK cells from congenic C57BL/6- ptprca (CD45.1+) mice were transferred into RMA-erbB2 tumor-bearing RAG-1–/– recipient mice (CD45.2+) cell on days 0 and 1. Three mice at each time point were then sacrificed on days 1, 2, and 5 following tumor injection, and spleens were harvested and i.p. washes were performed to determine the number of CD45.1+ cells present.

Statistical analysis

The Mann-Whitney U test was used for statistical analysis. Values of p < 0.05 were considered significant.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Expression of the chimeric anti-erbB2 receptor in primary mouse NK cells

The genetic modification of primary mouse NK cells with scFv chimeric receptors using retroviral-based transduction methods has proven difficult. To address this, we used the Amaxa Nucleofector system to gene modify mouse NK cells with the scFv {alpha}-erbB2-CD28-{zeta} chimeric receptor (Fig. 1A). Using this method, high level expression of the {alpha}-erbB2 receptor was achieved in mouse NK cells following staining with a c-myc tag mAb specifically recognizing a c-myc tag epitope incorporated into the extracellular domain of the chimeric receptor (46 ± 10%, n = 7; Fig. 1B). Equivalent levels of expression of autonomous GFP were also observed in control mouse NK cells (49 ± 11%, n = 7; Fig. 1C). Importantly, the transfected NK cell populations were TCRβ negative (data not shown). Cell viability ranged between 60 and 90% following electroporation.


Figure 1
View larger version (40K):
[in this window]
[in a new window]

  		FIGURE 1. Gene modification of primary murine NK cells with the anti-erbB2 chimeric receptor. A, Schematic representation of the scFv-anti-erbB2-CD28-{zeta} receptor. The chimeric receptor consisted of the VH and VL regions of the anti-erbB2 mAb joined by a flexible linker, a CD8-{alpha} membrane-proximal hinge region (MP), and the transmembrane (TM) and cytoplasmic regions of the mouse CD28 signaling chain fused to the intracellular domain of human TCR-{zeta}. B, The expression of the chimeric scFv anti-erbB2 receptor in mouse NK cells was analyzed following staining with an anti-tag Ab mAb and PE-labeled sheep anti-mouse Ig (thick line) or a secondary PE-conjugated Ab (thin line). C, Expression of GFP in transfected (thick line) vs nontransfected (thin line) NK cells was analyzed by flow cytometry. Results shown are representative of seven experiments performed.

 
Phenotypic characterization of gene-modified primary mouse NK cells

We next investigated whether expression of the chimeric scFv receptor had any affect on NK cell phenotype. We used flow cytometry to compare expression of a number of molecules expressed by {alpha}-erbB2-NK and control GFP-NK cells, including activation and inhibition receptors. In three independently performed experiments, we observed no difference in the expression of NK cell markers NK1.1 or DX5 between GFP-NK and {alpha}-erbB2-NK cells (Fig. 2, A and B). There was also no difference in the level of expression of the CD11b marker between transfected NK cells (Fig. 2C). In addition, comparable expression of inhibitory receptors Ly49A, KLRG1, CD94, and the activatory receptor NKG2D, was observed between {alpha}-erbB2-NK and GFP-NK cells (Fig. 2, D–F). The levels of expression of the costimulatory receptor CD27 and activation markers CD69 and CD25 were also expressed at similar levels between the transfected NK cell types (Fig. 2, H–J). These data indicated that transfection of mouse NK cells with the scFv chimeric receptor has not phenotypically altered expression of a number of important NK cell-associated markers.


Figure 2
View larger version (15K):
[in this window]
[in a new window]

  		FIGURE 2. Phenotypic characterization of gene-modified primary mouse NK cells. The surface expression of various NK cell markers, activation markers, and activation/inhibition receptors was analyzed by flow cytometry following staining with appropriate Abs. Cells used for analysis were gated on either anti-tag positive cells (representing anti-erbB2 receptor expressing cells; thick line) or gated on GFP positive cells (representing control NK cells; thin line), or on unstained anti-erbB2-NK cells (dotted line). There was no significant difference in expression of the following molecules between anti-erbB2 or GFP transfected NK cells; NK1.1 (A), DX5 (B), CD11b (C), Ly49A (D), KLRG1 (E), NKG2D (F), CD94 (G), CD27 (H), CD69 (I), or CD25 (J). Results shown are representative of three independent experiments.

 
Ag-specific cytotoxicity mediated by anti-erbB2-NK cells

Although NK cells can mediate effective killing of target cells, they are often inhibited by recognition of MHC class I molecule. Indeed, this is supported by our data demonstrating low killing by GFP-NK effector cells of the MHC class I+ lymphoma cell line RMA-erbB2 compared with the class I-deficient RMA-S-erbB2 cell line (Fig. 3). To determine whether our gene-modified NK cells expressing the {alpha}-erbB2 chimeric receptor could overcome MHC-class I inhibition we assessed their ability to kill RMA cells, either expressing the erbB2 TAA (RMA-erbB2) or not. Importantly, the level of MHC class I expression on RMA-erbB2 and RMA cells was equivalent (Fig. 4). We demonstrated at least a two fold increase in the level of killing of RMA-erbB2 cells by {alpha}-erbB2-NK cells compared with control GFP-NK cells (Fig. 5A). This enhanced killing was erbB2 Ag-specific because {alpha}-erbB2-NK and GFP-NK cells mediated comparable lysis of RMA parental cells (Fig. 5B). We next determined whether anti-erbB2-NK cells could increase killing of another erbB2+ cell line. In this experiment we demonstrated enhanced killing by anti-erbB2-NK cells of a mouse melanoma cell line B16 expressing erbB2 Ag (B16-F10-erbB2) compared with control GFP-NK cells (Fig. 5C). Again this was erbB2-specific because equivalent killing of parental B16-F10 cells by anti-erbB2 or GFP-NK cells was observed (Fig. 5D). We also showed that expression of the scFv receptor or GFP had no impact on the endogenous cytotoxic ability of NK cells. We demonstrated comparable cytotoxicity of a NK cell-sensitive target cell line, YAC-1, by either non-transfected 7-day IL-2-activated NK cells or gene-modified NK cells (Fig. 5E). These data demonstrated that expression of the scFv receptor targeting TAA could endow primary mouse NK cells with the ability to overcome MHC class I-mediated inhibition and kill NK cell-sensitive tumors.


Figure 3
View larger version (9K):
[in this window]
[in a new window]

  		FIGURE 3. MHC class I inhibition of NK cell cytotoxicity. GFP-NK effector cells were used in a 4 h 51Cr release assay against the MHC class I+ RMA-erbB2 cell line or class I deficient RMA-S-erbB2 tumor cell line. GFP-NK cells were able to more effectively kill the RMA-S-erbB2 cell line (open squares) compared with the RMA-erbB2 cell line (closed squares; *, p < 0.05, as determined by a Mann-Whitney U test). Results are representative of three independent experiments.

 

Figure 4
View larger version (10K):
[in this window]
[in a new window]

  		FIGURE 4. Expression of MHC class I on RMA tumor cells. MHC class I expression on RMA parental (thick line) and RMA-erbB2 (thin line) tumor cells was determined by staining cells with a PE-conjugated Ab specific for mouse H2kb. Unstained RMA tumor cells (dotted line) were used as a control.

 

Figure 5
View larger version (19K):
[in this window]
[in a new window]

  		FIGURE 5. Enhanced cytotoxicity of erbB2+ tumor cells by anti-erbB2 NK cells. A, Gene modification of primary mouse NK cells with the scFv chimeric anti-erbB2 receptor enhanced killing of RMA-erbB2 target cells compared with GFP-NK cells. B, Anti-erbB2 NK and GFP-NK cells equivalently killed RMA parental cells. C, Gene modification of primary mouse NK cells with the scFv chimeric anti-erbB2 receptor enhanced killing of B16-F10-erbB2 target cells compared with GFP-NK cells. D, Anti-erbB2 NK and GFP-NK cells equivalently killed B16-F10 parental cells. E, Anti-erbB2 NK, GFP-NK, or untransfected cells equivalently killed the NK cell sensitive target YAC-1. (*, p < 0.05, as determined by a Mann-Whitney U test). Results are expressed as average ± SEM of triplicates from three independent experiments.

 
Target cell lysis mediated by gene-modified NK cells was perforin dependent

It has been reported that NK cells lyse their targets predominantly via the granule exocytosis pathway involving perforin; however, they can also mediate apoptotic activity through FasL or TRAIL pathways (5, 32). To determine the mechanism of killing used by our gene-modified primary mouse NK cells, we genetically modified NK cells from C57BL/6 WT, perforin-deficient (pfp–/–), and gld (mutant FasL) mice. Importantly, the level of expression of the scFv chimeric receptor was comparable in NK cells derived from WT and gene-targeted mice (data not shown). It is also important to note that previous studies have shown that other functional pathways of NK cells from perforin-deficient mice (i.e., FasL-mediated killing) are intact (33). In cytotoxicity assays, we demonstrated no killing of RMA-erbB2 target cells by {alpha}-erbB2 NK cells derived from pfp–/– mice (Fig. 6A). In contrast, the sensitivity of RMA-erbB2 cells to {alpha}-erbB2 NK cells derived from gld mice or WT mice was similar (Fig. 6A). As further specificity controls we observed comparable background killing of RMA-erbB2 by GFP-NK cells and RMA-parental cells by either {alpha}-erbB2 or GFP-NK cells derived from WT and gld mice (Fig. 6, B–D). These data demonstrated that gene-modified primary mouse NK cells mediated Ag-specific cytotoxicity through a perforin-dependent mechanism.


Figure 6
View larger version (15K):
[in this window]
[in a new window]

  		FIGURE 6. Cytotoxicity of erbB2+ tumor cells by anti-erbB2 NK cells is perforin-dependent. Gene-modified NK cells derived from WT, perforin-deficient (pfp–/–), or gld (Fas ligand mutant) mice were used in a 4 h 51Cr release assay. A, Killing of RMA-erbB2 target cells by anti-erbB2 NK cells derived from pfp–/–, but not WT or gld mice, was completely abrogated. Equivalent background killing of RMA-erbB2 tumor cells (B) and RMA parental cells (C) by GFP-NK cells or RMA-parental cells by {alpha}-erbB2 NK cells (D) derived from either WT or gld mice. (*, p < 0.05, **, p > 0.05 as determined by a Mann-Whitney U test). Results shown are representative of two independent experiments.

 
Ag-specific inhibition of tumor growth mediated by anti-erbB2-NK cells

We next assessed the ability of gene-modified mouse NK cells expressing the {alpha}-erbB2 chimeric receptor to mediate Ag-specific inhibition of tumor growth in vivo. Tumor cells (RMA-parental or RMA-erbB2) were injected i.p. into RAG-1–/– mice that then received early transfer (days 0, 1) or delayed transfer (days 3, 4) of 2 x 106 gene-modified NK cells ({alpha}-erbB2-NK or GFP-NK cells). In these experiments, we demonstrated significantly increased survival of mice with RMA-erbB2 tumor that received {alpha}-erbB2 gene-modified NK cells delivered at early or at later time points (Fig. 7, A and B). This effect was Ag-specific because there was no significant increase in survival of mice with RMA-erbB2 that received control GFP-NK cells. Furthermore, {alpha}-erbB2 NK cells had no anti-tumor effect in mice injected with RMA parental tumor. In another experiment we demonstrated that coadministration of high dose IL-2 (200,000 IU/ml) with gene-modified NK cells did not improve the anti-tumor effect in mice (data not shown). We also investigated the persistence of our adoptively transferred gene-modified NK cells by using donor NK cells from congenic C57BL/6-PTPRCa mice. In these experiments we could not detect significant persistence of these cells 7 days post transfer in recipient mice (data not shown). To determine whether increasing the number of doses of anti-erbB2-NK cells could enhance the anti-tumor response, RAG-1–/– recipient mice bearing RMA-erbB2 tumor were injected i.p with 2 x 106 anti-erbB2-NK or GFP-NK cells on days 0, 1, 2, 3. We demonstrated that increasing the number of doses of anti-erbB2-NK significantly enhanced the survival of mice (~35% mice tumor-free) compared with previous experiments involving two injections of gene-modified NK cells (Fig. 8). Mice that received control GFP-NK cells or RMA-erbB2 tumor alone rapidly succumbed to disease. Collectively, this data demonstrated for the first time that adoptive transfer of gene-modified primary mouse NK cells could mediate an effective Ag-specific tumor response in vivo.


Figure 7
View larger version (16K):
[in this window]
[in a new window]

  		FIGURE 7. Enhanced survival of tumor-bearing mice after adoptive transfer of {alpha}-erbB2 NK cells. Groups of 5–10 mice were injected i.p. with 2 x 105 RMA-erbB2 tumor alone (closed squares) or injected with RMA-erbB2 tumor and treated with two doses of 2 x 106 {alpha}-erbB2-NK cells (closed triangles) or GFP-NK cells (open triangles) on days 0 and 1 (A) or days 3 and 4 (B). Mice bearing RMA tumor were treated with 2 x 106 {alpha}-erbB2-NK cells (open squares). Mice bearing RMA-erbB2 tumor and treated with {alpha}-erbB2 NK cells showed significantly increased survival compared with mice treated with control GFP NK cells (*, p < 0.05, as determined by a Mann-Whitney U test). Results shown are representative of two experiments performed. Arrows indicated days of NK cell transfer.

 

Figure 8
View larger version (10K):
[in this window]
[in a new window]

  		FIGURE 8. Increased transfer of {alpha}-erbB2 NK cells leads to tumor free survival of mice. Groups of six mice were injected i.p. with 2 x 105 RMA-erbB2 tumor alone (closed squares) or injected with RMA-erbB2 tumor and treated with four doses of 2 x 106 {alpha}-erbB2-NK cells (closed triangles) or GFP-NK cells (open triangles) on days 0, 1, 2, and 3. Mice bearing RMA-erbB2 tumor and treated with four doses of {alpha}-erbB2 NK cells showed significantly increased survival compared with mice treated with control GFP NK cells (*, p < 0.05, as determined by a Mann-Whitney U test). Arrows indicated days of NK cell transfer.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
The use of NK cells for cancer immunotherapy is gaining much attention. The most promising developments have come from the transfer of allogeneic NK cells in the allogeneic transplant stem cell setting (34). Recent results have demonstrated that treatment of acute myeloid leukemia patients with alloreactive NK cells could substantially increase their survival without associated graft-vs-host effects (14). Nevertheless, improvements in the use of alloreactive NK cells are required given that these cells had no apparent effect in patients with acute lymphoid leukemia (14). Other therapies involving the transfer of IL-2-activated LAK cells have shown only modest anti-tumor effects in patients. This is due in part to their nonspecific nature and to HLA-mediated inhibitory signals induced by interaction with NK cell inhibitory receptors (9). A novel way to overcome these problems and enhance NK cell anti-tumor activity involves their genetic modification with scFv chimeric receptors that can specifically recognize TAA. To test this we used the Amaxa transfection system to genetically engineer primary mouse NK cells with a chimeric scFv receptor with specific recognition for the erbB2 TAA. Importantly, the expression of the chimeric receptor in mouse NK cells did not interfere with their natural cytotoxic capability against NK-sensitive target cells. We demonstrated that NK cells engineered with the scFv anti-erbB2 receptor could significantly enhance killing of an essentially NK-insensitive lymphoma cell line in an erbB2+ Ag-specific manner. Furthermore, for the first time, we demonstrated that adoptive transfer of receptor-modified primary mouse NK cells could specifically enhance the survival of tumor-bearing mice.

A number of studies have shown that gene modification of various mouse and human NK cell lines with scFv chimeric receptors could specifically enhance their anti-tumor activity in vitro (25, 27, 35, 36). Another report demonstrated that human primary NK cells expressing an anti-CD19 scFv receptor could specifically kill CD19+ leukemic cells (28). Nevertheless, the ability of primary NK cells to mediate Ag-specific anti-tumor effects in vivo has not been formally tested. This has been due to difficulties in using retroviral-based approaches to efficiently express chimeric scFv receptors in NK cells, which is particularly the case for primary mouse NK cells. In our study, we were able to demonstrate proof of principle that adoptively transferred gene-modified primary mouse NK cells could specifically mediate anti-tumor inhibition in vivo. Indeed, mice treated with four doses of anti-erbB2-NK cells resulted in ~35% long term survivors. Nevertheless, these experiments were performed in RAG-1–/– mice where the presence of endogenous NK cells may have competed for important growth factors and cytokines limiting both the persistence and activity of gene-modified NK cells. Persistence could potentially be improved by a non-myeloablative conditioning regimen before adoptive NK cell transfer to produce a conducive cytokine environment. This type of approach has been demonstrated to enhance the therapeutic efficacy of adoptively transferred T cells in both mouse models and in patients (37, 38, 39, 40, 41). Alternatively, in future experiments, the use of RAG{gamma}c–/– recipient mice (that also lack NK cells) may overcome this problem in an experimental setting and result in increased persistence of gene-modified NK cells. The combination of lymphodepletion and CD34+ hematopoietic stem cells has shown to further enhance the activity of transferred T cells (42). Thus, it would be of interest in future studies to test whether these types of regimens can similarly increase persistence and anti-tumor effects of transferred gene-modified NK cells.

The anti-tumor effects observed with adoptive transfer of LAK cells in melanoma patients have been dependent on coadministration of high dose IL-2 (43). However, in our mouse model coadministration of high dose IL-2 did not improve the anti-tumor effects by gene-modified NK cells. There have been reports that other cytokines such as IL-15 are required for the persistence of NK cells (44, 45). Thus, it would be interesting to test in our model whether cytokines such as IL-15 may be of some benefit.

To achieve receptor expression in this study we used a non-viral vector system, which has attractive safety aspects compared with viral-based systems, particularly when considering clinical applications. In addition, expression levels using this method, although high, were largely transient, lasting ~72 h. This provides added safety by reducing the risk of long-term autoimmunity associated with prolonged presence of potentially autoreactive cells. Nevertheless, improvements in safety and efficiency of gene transfer technology for primary mouse NK cells may lead to increased anti-tumor effects. A recent report using lentivirus transduction demonstrated long term and stable expression of GFP in mouse NK cells in vitro without affecting NK cell phenotype and function (46). It will be of interest in future experiments to test whether the use of lentiviral vectors can maintain stable expression of scFv receptor genes in mouse and human NK cells in vivo after adoptive transfer with no associated autoimmunity.

One of the advantages of using gene-modified primary mouse NK cells in this study has been the ability to begin to dissect the mechanisms used by these cells to mediate specific anti-tumor effects. In this study the use of gene-modified donor NK cells from various gene-targeted mice revealed that Ag-specific killing in vitro by these cells was perforin dependent. In contrast, lysis of erbB2+ target cells by gene-modified NK cells from gld mice was not affected. However, whether perforin and/or other lytic mediators such as IFN-{gamma} play an important role in the activity of gene-engineered NK cells in vivo remains to be determined. Understanding the mechanisms and effector molecules used by gene-modified NK cells may help in selection of tumor types to be targeted in future translation of this approach.

There are several issues which need to be addressed before using gene-modified NK cells in the clinic. Unlike for T cells, generation of sufficient numbers of gene-modified autologous NK cells may be problematic. However, a recent report demonstrated that it is possible to achieve greater than 1000-fold expansion of gene-modified human NK cells from PBMC following stimulation with K562 cells expressing 4-1BBL and IL-15 (28). Another consideration is whether gene-modified NK cells may cause autoimmune effects in the host after transfer. We were unable to assess this in the RAG model given that the erbB2 Ag was tumor-specific. However, the use of human erbB2+ transgenic mice may serve as a better model to evaluate potential autoimmunity from transferred gene-modified NK cells. This model will also enable us to assess the effect of self-Ag on anti-tumor immunity following NK cell transfer (47). In any case, if autoimmune problems were to arise, the incorporation of a suicide gene in the vector design could be used to eliminate these gene-modified NK cells. The use of HSV-thymidine kinase (48) or the cytoplasmic domain of Fas (49) are potential suicide gene candidates. The question of whether transferred gene-modified NK cells may induce transformation needs to be investigated particularly for gene-modification protocols involving retroviral or lentiviral vectors. Encouragingly, there have been no transforming events reported in patients following transfer of LAK cells or allogeneic NK cells in the hematopoietic transplant setting. Our recent study has demonstrated that CD4+CD25+ T regulatory cells can inhibit NK cell anti-tumor activity (50). The question of whether the activity of gene-modified NK cells can be similarly suppressed by T regulatory cells remains unknown. If this was found to be the case, the treatment of patients with cyclophosphamide or fludarabine before adoptive NK transfer may alleviate this problem.

In summary, we have demonstrated high level expression of the scFv anti-erbB2-CD28-{zeta} chimeric receptor in primary mouse NK cells and that adoptive transfer of these cells could mediate Ag-specific tumor inhibition in vivo. The use of this receptor containing the CD28 costimulatory signaling molecule was appropriate for mouse NK cells given that CD28-mediated signaling has been demonstrated in these cells (51, 52). However, the incorporation of other signaling domains into the receptor may result in even better activation of NK cells. An anti-CD19 scFv chimeric receptor containing the 4-1BB signaling domain linked in tandem with the TCR-{zeta} domain was shown to enhance human NK cell function compared with receptors containing either TCR-{zeta} or DAP10-signaling domains alone (28). Whether this type of receptor incorporating the 4-1BB signaling domain can enhance NK cell function and anti-tumor effects in vivo warrants further investigation. Previous studies have shown superior functional activity and trafficking by CD27hi NK cells (53). Thus comparison of different gene modified NK cell subsets (CD27hi vs CD27lo) may identify which subset to use for achieving optimal therapeutic effects. Overall, the results of this study have highlighted that use of gene-modified NK cells to overcome HLA-mediated inhibition is a novel and exciting prospect for cancer immunotherapy.


   Acknowledgments
 
We acknowledge the assistance of the Peter MacCallum Cancer Centre Experimental Animal Facility technicians for animal care.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by a National Health and Medical Research Council Program Grant and a Cancer Council of Victoria research grant. M.H.K. and P.K.D. were supported by National Health and Medical Research Council of Australia R.D. Wright Research Fellowships. M.J.S. was supported by a National Health and Medical Research Council Senior Principal Research Fellowship. Back

H.J.P. performed the research, analyzed the data, and wrote first draft of the paper. J.T.J. performed the research. M.J.S. analyzed the data. M.H.K. designed the research and analyzed the data. P.K.D. designed the research, analyzed the data, and wrote the manuscript.

2 M.H.K. and P.K.D. contributed equally as senior authors. Back

3 Address correspondence and reprint requests to Dr. Phillip K. Darcy and Dr. Michael H. Kershaw, Peter MacCallum Cancer Institute, Locked Bag 1, A’Beckett Street, Victoria, 8006, Australia. E-mail addresses: phil.darcy{at}petermac.org and michael.kershaw{at}petermac.org Back

4 Abbreviations used in this paper: LAK, lymphokine killer cells; scFv, single-chain variable fragment; TAA, tumor-associated Ags; FasL, Fas ligand; WT, wild type. Back

Received for publication April 17, 2008. Accepted for publication July 3, 2008.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Yokoyama, W. M., S. Kim, A. R. French. 2004. The dynamic life of natural killer cells. Annu. Rev. Immunol. 22: 405-429. [Medline]
  2. Ferlazzo, G., D. Thomas, S. L. Lin, K. Goodman, B. Morandi, W. A. Muller, A. Moretta, C. Munz. 2004. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. 172: 1455-1462. [Abstract/Free Full Text]
  3. Cerwenka, A., L. L. Lanier. 2001. Natural killer cells, viruses, and cancer. Nat. Rev. Immunol. 1: 41-49. [Medline]
  4. Smyth, M. J., J. M. Kelly, A. G. Baxter, H. Korner, J. D. Sedgwick. 1998. An essential role for tumor necrosis factor in natural killer cell-mediated tumor rejection in the peritoneum. J. Exp. Med. 188: 1611-1619. [Abstract/Free Full Text]
  5. Smyth, M. J., E. Cretney, K. Takeda, R. H. Wiltrout, L. M. Sedger, N. Kayagaki, H. Yagita, K. Okumura. 2001. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon {gamma}-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193: 661-670. [Abstract/Free Full Text]
  6. van den Broek, M. F., D. Kagi, R. M. Zinkernagel, H. Hengartner. 1995. Perforin dependence of natural killer cell-mediated tumor control in vivo. Eur. J. Immunol. 25: 3514-3516. [Medline]
  7. Smith, B. R., D. S. Rosenthal, K. A. Ault. 1985. Natural killer lymphocytes in hairy cell leukemia: presence of phenotypically identifiable cells with defective functional activity. Exp. Hematol. 13: 189-193. [Medline]
  8. Karre, K., H. G. Ljunggren, G. Piontek, R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678. [Medline]
  9. Lanier, L. L.. 1998. NK cell receptors. Annu. Rev. Immunol. 16: 359-393. [Medline]
  10. Chang, E., S. A. Rosenberg. 2001. Patients with melanoma metastases at cutaneous and subcutaneous sites are highly susceptible to interleukin-2-based therapy. J. Immunother. 24: 88-90. [Medline]
  11. Rosenberg, S.. 1985. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J. Natl. Cancer Inst. 75: 595-603. [Medline]
  12. Bordignon, C., C. Carlo-Stella, M. P. Colombo, A. De Vincentiis, L. Lanata, R. M. Lemoli, F. Locatelli, A. Olivieri, D. Rondelli, P. Zanon, S. Tura. 1999. Cell therapy: achievements and perspectives. Haematologica 84: 1110-1149. [Abstract/Free Full Text]
  13. Ruggeri, L., M. Capanni, M. Casucci, I. Volpi, A. Tosti, K. Perruccio, E. Urbani, R. S. Negrin, M. F. Martelli, A. Velardi. 1999. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94: 333-339. [Abstract/Free Full Text]
  14. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100. [Abstract/Free Full Text]
  15. Kershaw, M. H., J. T. Jackson, N. M. Haynes, M. W. Teng, M. Moeller, Y. Hayakawa, S. E. Street, R. Cameron, J. E. Tanner, J. A. Trapani, et al 2004. Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J. Immunol. 173: 2143-2150. [Abstract/Free Full Text]
  16. Kershaw, M. H., J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, et al 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12: 6106-6115. [Abstract/Free Full Text]
  17. Pinthus, J. H., T. Waks, V. Malina, K. Kaufman-Francis, A. Harmelin, I. Aizenberg, H. Kanety, J. Ramon, Z. Eshhar. 2004. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J. Clin. Invest. 114: 1774-1781. [Medline]
  18. Kershaw, M. H., J. A. Westwood, P. Hwu. 2002. Dual-specific T cells combine proliferation and antitumor activity. Nat. Biotechnol. 20: 1221-1227. [Medline]
  19. Brentjens, R. J., J. B. Latouche, E. Santos, F. Marti, M. C. Gong, C. Lyddane, P. D. King, S. Larson, M. Weiss, I. Riviere, M. Sadelain. 2003. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9: 279-286. [Medline]
  20. Cheadle, E. J., D. E. Gilham, F. C. Thistlethwaite, J. A. Radford, R. E. Hawkins. 2005. Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br. J. Haematol. 129: 322-332. [Medline]
  21. Maher, J., R. J. Brentjens, G. Gunset, I. Riviere, M. Sadelain. 2002. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR{zeta}/CD28 receptor. Nat. Biotechnol. 20: 70-75. [Medline]
  22. Kahlon, K. S., C. Brown, L. J. Cooper, A. Raubitschek, S. J. Forman, M. C. Jensen. 2004. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 64: 9160-9166. [Abstract/Free Full Text]
  23. Hombach, A., C. Schlimper, E. Sievers, S. Frank, H. H. Schild, T. Sauerbruch, I. G. Schmidt-Wolf, H. Abken. 2006. A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3{zeta}-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells. Gut 55: 1156-1164. [Abstract/Free Full Text]
  24. Westwood, J. A., M. J. Smyth, M. W. Teng, M. Moeller, J. A. Trapani, A. M. Scott, F. E. Smyth, G. A. Cartwright, B. E. Power, D. Honemann, et al 2005. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc. Natl. Acad. Sci. USA 102: 19051-19056. [Abstract/Free Full Text]
  25. Uherek, C., T. Tonn, B. Uherek, S. Becker, B. Schnierle, H. G. Klingemann, W. Wels. 2002. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood 100: 1265-1273. [Abstract/Free Full Text]
  26. Schirrmann, T., G. Pecher. 2001. Tumor-specific targeting of a cell line with natural killer cell activity by asialoglycoprotein receptor gene transfer. Cancer Immunol. Immunother. 50: 549-556. [Medline]
  27. Muller, T., C. Uherek, G. Maki, K. U. Chow, A. Schimpf, H. G. Klingemann, T. Tonn, W. S. Wels. 2008. Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunol. Immunother. 57: 411-423. [Medline]
  28. Imai, C., S. Iwamoto, D. Campana. 2005. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 106: 376-383. [Abstract/Free Full Text]
  29. Eshhar, Z., T. Waks, A. Bendavid, D. G. Schindler. 2001. Functional expression of chimeric receptor genes in human T cells. J. Immunol. Methods 248: 67-76. [Medline]
  30. Finney, H. M., A. D. Lawson, C. R. Bebbington, A. N. Weir. 1998. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161: 2791-2797. [Abstract/Free Full Text]
  31. Darcy, P. K., M. H. Kershaw, J. A. Trapani, M. J. Smyth. 1998. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody: redirected Fas ligand-mediated lysis of colon carcinoma. Eur. J. Immunol. 28: 1663-1672. [Medline]
  32. Takeda, K., M. J. Smyth, E. Cretney, Y. Hayakawa, N. Yamaguchi, H. Yagita, K. Okumura. 2001. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-{gamma}-dependent suppression of subcutaneous tumor growth. Cell. Immunol. 214: 194-200. [Medline]
  33. Wallin, R. P., V. Screpanti, J. Michaelsson, A. Grandien, H. G. Ljunggren. 2003. Regulation of perforin-independent NK cell-mediated cytotoxicity. Eur. J. Immunol. 33: 2727-2735. [Medline]
  34. Ruggeri, L., A. Mancusi, E. Burchielli, F. Aversa, M. F. Martelli, A. Velardi. 2007. Natural killer cell alloreactivity in allogeneic hematopoietic transplantation. Curr. Opin. Oncol. 19: 142-147. [Medline]
  35. Tran, A. C., D. Zhang, R. Byrn, M. R. Roberts. 1995. Chimeric zeta-receptors direct human natural killer (NK) effector function to permit killing of NK-resistant tumor cells and HIV-infected T lymphocytes. J. Immunol. 155: 1000-1009. [Abstract]
  36. Roberts, M. R., K. S. Cooke, A. C. Tran, K. A. Smith, W. Y. Lin, M. Wang, T. J. Dull, D. Farson, K. M. Zsebo, M. H. Finer. 1998. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing {zeta} or {gamma} signaling domains. J. Immunol. 161: 375-384. [Abstract/Free Full Text]
  37. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854. [Abstract/Free Full Text]
  38. Chang, A. E., S. Y. Shu, T. Chou, R. Lafreniere, S. A. Rosenberg. 1986. Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors. Cancer Res. 46: 3426-3430. [Abstract/Free Full Text]
  39. Hu, H. M., C. H. Poehlein, W. J. Urba, B. A. Fox. 2002. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 62: 3914-3919. [Abstract/Free Full Text]
  40. Lenz, D. C., S. K. Kurz, E. Lemmens, S. P. Schoenberger, J. Sprent, M. B. Oldstone, D. Homann. 2004. IL-7 regulates basal homeostatic proliferation of antiviral CD4+T cell memory. Proc. Natl. Acad. Sci. USA 101: 9357-9362. [Abstract/Free Full Text]
  41. North, R. J.. 1984. Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol. Immunother. 16: 175-181. [Medline]
  42. Wrzesinski, C., C. M. Paulos, L. Gattinoni, D. C. Palmer, A. Kaiser, Z. Yu, S. A. Rosenberg, N. P. Restifo. 2007. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J. Clin. Invest. 117: 492-501. [Medline]
  43. Rosenberg, S. A., M. T. Lotze, J. C. Yang, S. L. Topalian, A. E. Chang, D. J. Schwartzentruber, P. Aebersold, S. Leitman, W. M. Linehan, C. A. Seipp, et al 1993. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 85: 622-632. [Abstract/Free Full Text]
  44. Cooper, M. A., J. E. Bush, T. A. Fehniger, J. B. VanDeusen, R. E. Waite, Y. Liu, H. L. Aguila, M. A. Caligiuri. 2002. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100: 3633-3638. [Abstract/Free Full Text]
  45. Prlic, M., B. R. Blazar, M. A. Farrar, S. C. Jameson. 2003. In vivo survival and homeostatic proliferation of natural killer cells. J. Exp. Med. 197: 967-976. [Abstract/Free Full Text]
  46. Tran, J., S. K. Kung. 2007. Lentiviral vectors mediate stable and efficient gene delivery into primary murine natural killer cells. Mol. Ther. 15: 1331-1339. [Medline]
  47. Piechocki, M. P., Y. S. Ho, S. Pilon, W. Z. Wei. 2003. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J. Immunol. 171: 5787-5794. [Abstract/Free Full Text]
  48. Cohen, J. L., O. Boyer, V. Thomas-Vaslin, D. Klatzmann. 1999. Suicide gene-mediated modulation of graft-versus-host disease. Leuk. Lymphoma 34: 473-480. [Medline]
  49. Thomis, D. C., S. Marktel, C. Bonini, C. Traversari, M. Gilman, C. Bordignon, T. Clackson. 2001. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 97: 1249-1257. [Abstract/Free Full Text]
  50. Smyth, M. J., M. W. Teng, J. Swann, K. Kyparissoudis, D. I. Godfrey, Y. Hayakawa. 2006. CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176: 1582-1587. [Abstract/Free Full Text]
  51. Walker, W., M. Aste-Amezaga, R. A. Kastelein, G. Trinchieri, C. A. Hunter. 1999. IL-18 and CD28 use distinct molecular mechanisms to enhance NK cell production of IL-12-induced IFN-{gamma}. J. Immunol. 162: 5894-5901. [Abstract/Free Full Text]
  52. Wilson, J. L., J. Charo, A. Martin-Fontecha, P. Dellabona, G. Casorati, B. J. Chambers, R. Kiessling, M. T. Bejarano, H. G. Ljunggren. 1999. NK cell triggering by the human costimulatory molecules CD80 and CD86. J. Immunol. 163: 4207-4212. [Abstract/Free Full Text]
  53. Hayakawa, Y., M. J. Smyth. 2006. CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity. J. Immunol. 176: 1517-1524. [Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pegram, H. J.
Right arrow Articles by Darcy, P. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pegram, H. J.
Right arrow Articles by Darcy, P. K.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Lymphoma

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS